Table 3.
Effect of Antibody Content on Characteristics of eTmab-PPLNs.a,b
| PPLNs-to-Tmab (wt/wt) | PPLNs | eTmab-PPLNs | BE, % | ||||
|---|---|---|---|---|---|---|---|
| Size, nm | PDI | ζ potential, mV | Size, nm | PDI | ζ potential, mV | ||
| 1:4 | 217.4 ± 13.36 | 0.202 ± 0.029 | 3.010 ± 0.150 | 35.09 ± 2.60 | |||
| 1:2 | 207.9 ± 9.396 | 0.125 ± 0.021 | 1.800 ± 0.070 | 30.72 ± 1.63 | |||
| 1:1 | 179.3 ± 0.707 | 0.078 ± 0.020 | 20.8 ± 0.721 | 199.1 ± 4.026 | 0.098 ± 0.009 | 0.895 ± 0.248 | 51.01 ± 3.85 |
| 2:1 | 192.5 ± 9.843 | 0.102 ± 0.032 | 0.553 ± 0.360 | 39.09 ± 3.26 | |||
| 4:1 | 192.6 ± 3.786 | 0.095 ± 0.034 | 0.705 ± 0.261 | 45.68 ± 1.48 | |||
Abbreviations: BE, binding efficiency; eTmab-PPLNs, electrostatically conjugated trastuzumab-bearing PPLNs; PDI, polydispersity index; PLGA, PPLNs, poly (d, l-lactide-co-glycolide)/polyethylenimine/lipid nanoparticles;.
a BE is the percentage of the amount of adsorbed Tmab and the total amount of Tmab added.
b Data are represented as mean ± SD (n = 3). SD, standard deviation